Table 2 Characteristics and clinical outcomes of pulmonary edema group
| Â | PE group |
|---|---|
|  | n = 16 |
Cause of PE | |
 Cardiogenic, n (%) | 2 (12.5) |
 Noncardiogenic, n (%) | 14 (87.5) |
Onset of PE (gestational age), median [IQR] | 31 + 2 [25 + 5, 34 + 1] |
 Pregnancy, n (%) | 14 (87.5) |
 Postpartum, n (%) | 2 (12.5) |
Duration from admission to onset of PE (days), median [IQR] | 3.0 [1.8, 7.3] |
Duration from onset of PE to delivery (days), median [IQR] | 0 [0.0, 1.0] |
 0 days, n (%) | 9 (64.3) |
 1 day, n (%) | 2 (14.3) |
 8 days, n (%) | 1 (7.1) |
 10 days, n (%) | 1 (7.1) |
 24 days, n (%) | 1 (7.1) |
Combination of use | |
 Free, n (%) | 3 (18.8) |
 Tocolytic agents, n (%) | 3 (18.8) |
 Tocolytic agents+betamethasone, n (%) | 10 (62.5) |
Duration from administration of ritodrine hydrochloride to onset of PE (days), median [IQR] | 4.0 [4.0, 31.0] |
Duration from administration of magnesium sulfate to onset of PE (days), median [IQR] | 2.0 [1.0, 5.0] |
Duration from last administration of betamethasone to onset of PE (days), median [IQR] | 0 [0.0, 1.0] |